Table 3. Univariable and multivariable analysis of late intrahepatic recurrence-free survival and factors of baseline and at three and six months after initial curative treatment.
| Factors | Univariable | Multivariable (three months) | Multivariable (six months) | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Baseline factors | |||||||
| Age (continuous) | 1.02 (1.01–1.03) | < 0.001 | 1.02 (1.01–1.03) | 0.001 | 1.01 (1.00–1.02) | 0.005 | |
| Sex (male) | 1.22 (1.03–1.45) | 0.02 | 1.32 (1.08–1.63) | 0.008 | 1.36 (1.09–1.69) | 0.006 | |
| Diabetes (yes) | 1.31 (1.10–1.56) | 0.002 | 1.20 (0.97–1.48) | 0.10 | 1.20 (0.96–1.49) | 0.11 | |
| Hypertension (yes) | 1.12 (0.96–1.30) | 0.16 | - | - | - | - | |
| Etiology (HCV vs. HBV) | 1.76 (1.35–2.31) | < 0.001 | 1.06 (0.74–1.51) | 1.00 | 1.01 (0.69–1.46) | 1.00 | |
| Etiology (alcohol/others vs. HBV) | 1.08 (0.85–1.37) | 0.99 | 0.94 (0.69–1.27) | 1.00 | 0.92 (0.67–1.26) | 1.00 | |
| Liver cirrhosis (yes) | 1.60 (1.40–1.85) | < 0.001 | 1.37 (1.15–1.62) | < 0.001 | 1.35 (1.14–1.61) | 0.001 | |
| Initial treatment (LAT vs. SR) | 1.98 (1.73–2.28) | <0.001 | 1.78 (1.50–2.11) | < 0.001 | 1.75 (1.47–2.08) | < 0.001 | |
| At three months | |||||||
| mALBI grade (2a vs. 1) | 1.50 (1.25–2.80) | < 0.001 | 1.33 (1.04–1.70) | 0.02 | |||
| mALBI grade (2b/3 vs. 1) | 2.05 (1.67–2.51) | < 0.001 | 1.42 (1.03–1.94) | 0.03 | |||
| mALBI (increment than baseline) | 1.10 (0.90–1.35) | 0.36 | - | - | |||
| AFP (increment than baseline) | 1.31 (1.11–1.55) | 0.002 | 1.00 (1.00–1.00) | 0.27 | |||
| PIVKA-II (increment than baseline) | 1.32 (1.09–1.61) | 0.006 | 1.00 (1.00–1.00) | 0.82 | |||
| ANC (increment than baseline) | 1.12 (0.97–1.29) | 0.11 | - | - | |||
| ALC (increment than baseline) | 0.89 (0.78–1.02) | 0.10 | - | - | |||
| AMC (increment than baseline) | 0.90 (0.78–1.03) | 0.90 | - | - | |||
| NLR (increment than baseline) | 1.17 (1.01–1.34) | 0.03 | 0.94 (0.85–1.05) | 0.30 | |||
| PLR (increment than baseline) | 1.41 (1.22–1.60) | < 0.001 | 1.01 (1.00–1.01) | 0.001 | |||
| LMR (increment than baseline) | 0.98 (0.85–1.13) | 0.81 | - | - | |||
| SII (increment than baseline) | 1.25 (1.08–1.45) | 0.002 | 1.00 (1.00–1.00) | 1.00 | |||
| APRI (increment than baseline) | 0.90 (0.79–1.04) | 0.15 | - | - | |||
| ALRI (increment than baseline) | 1.04 (0.90–1.19) | 0.61 | - | - | |||
| At six months | |||||||
| mALBI grade (2a vs 1) | 1.71 (1.42–2.06) | < 0.001 | 1.30 (0.98–1.71) | 0.07 | |||
| mALBI grade (2b/3 vs 1) | 2.25 (1.80–2.79) | < 0.001 | 1.61 (1.13–2.30) | 0.006 | |||
| mALBI (increment than baseline) | 1.27 (0.92–1.67) | 0.09 | - | - | |||
| AFP (increment than baseline) | 1.00 (0.86–1.17) | 0.98 | - | - | |||
| PIVKA-II (increment than baseline) | 0.84 (0.71–0.99) | 0.03 | 1.00 (1.00–1.00) | 0.94 | |||
| ANC (increment than baseline) | 0.90 (0.79–1.03) | 0.90 | - | - | |||
| ALC (increment than baseline) | 0.99 (0.86–1.14) | 0.88 | - | - | |||
| AMC (increment than baseline) | 0.87 (0.76–1.00) | 0.05 | 1.00 (1.00–1.00) | 0.03 | |||
| NLR (increment than baseline) | 0.93 (0.81–1.07) | 0.32 | - | - | |||
| PLR (increment than baseline) | 0.93 (0.81–1.06) | 0.26 | - | - | |||
| LMR (increment than baseline) | 1.00 (0.87–1.14) | 0.95 | - | - | |||
| SII (increment than baseline) | 0.95 (0.83–1.09) | 0.43 | - | - | |||
| APRI (increment than baseline) | 1.04 (0.90–1.19) | 0.60 | - | - | |||
| ALRI (increment than baseline) | 0.98 (0.86–1.13) | 0.79 | - | - | |||
HR = hazard ratio, CI = confidence interval, HCV = hepatitis C virus, HBV = hepatitis B virus, LAT = local ablation therapy, SR = surgical resection, mALBI = modified albumin-bilirubin, AFP = α-fetoprotein, PIVKA-II = protein induced by vitamin K antagonist-II, ANC = absolute neutrophil count, ALC = absolute lymphocyte count, AMC = absolute monocyte count, NLR = neutrophil-to-lymphocyte ratio, LMR = lymphocyte-to-monocyte ratio, PLR = platelet-to-lymphocyte ratio, SII = systemic immune-inflammation index, APRI = aspartate aminotransferase-to-platelet ratio, ALRI = aspartate aminotransferase-to-lymphocyte ratio.